Stroke causes sudden loss of brain function due to interrupted blood supply (ischaemic, 80%) or bleeding (haemorrhagic, 20%). Recovery depends on stroke severity, location, and promptness of acute treatment. Rehabilitation in the first months is critical; recovery extends over years through neuroplasticity and compensatory mechanisms.
Acute stroke management begins with imaging (CT/MRI) to confirm type and location. Ischaemic stroke is treated with thrombolysis (intravenous tissue plasminogen activator, tPA) within 4.5 hours or mechanical thrombectomy within 24 hours in selected cases, restoring blood flow and minimising brain damage. Rehabilitation commences in hospital and continues in inpatient or outpatient settings. Physiotherapy restores motor function through task-specific training, constraint-induced movement therapy (CIMT), and progressive resistance exercise. Speech and language therapy addresses aphasia, dysarthria, and swallowing dysfunction. Occupational therapy retains activities of daily living independence. Psychological support manages depression and anxiety, common post-stroke complications. Medications prevent recurrence: antiplatelet therapy (aspirin, clopidogrel), anticoagulation (in atrial fibrillation), antihypertensives, and statins. Cognitive rehabilitation supports attention, memory, and executive dysfunction.
Acupuncture is widely practised in stroke recovery, with some trials suggesting modest improvements in motor function and spasticity; quality of evidence remains variable. Traditional Chinese medicine herbal formulas are explored, though large-scale clinical validation is limited. Mirror therapy (practising movements whilst observing mirror reflection of the unaffected limb) is a low-cost adjunct showing promise for motor recovery in some populations. Mindfulness-based stress reduction and yoga may support emotional recovery and functional adaptation.
Stem cell therapy is studied for stroke recovery, with bone marrow-derived stem cells, mesenchymal stem cells, and neural stem cells evaluated in clinical trials. Proposed mechanisms include neuroprotection, reduction of inflammation, promotion of angiogenesis (new blood vessel formation), and neurogenesis (new neurone formation). Several Phase 2 trials have reported improvements in motor function when administered within months of acute stroke; outcomes vary, and clinical efficacy is not yet established. Candidate assessment typically focuses on chronic stroke (>6 months) with residual motor or cognitive deficits unsuitable for further conventional rehabilitation.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Acute thrombolysis (tPA) | Standard | Strong | €2,000–€5,000 | Low | 1–2 weeks |
| Mechanical thrombectomy | Standard | Strong | €5,000–€12,000 | Medium | 2–4 weeks |
| Physiotherapy & motor rehabilitation | Standard | Strong | €60–€150 per session | Low | Ongoing |
| Speech & occupational therapy | Standard | Strong | €60–€150 per session | Low | Ongoing |
| Acupuncture | Alternative | Moderate | €60–€120 per session | Low | Immediate |
| Mirror therapy | Alternative | Moderate | €50–€200/month | Low | Ongoing |
| Stem cell therapy for chronic stroke | Regenerative | Investigational | €20,000–€40,000 | Medium | 4–8 weeks |
Thrombolysis is most effective within 4.5 hours of symptom onset. Mechanical thrombectomy may benefit selected patients up to 24 hours post-stroke. Rapid hospital presentation maximises treatment options.
Rapid recovery occurs in the first 3 months; meaningful improvement continues for 6–12 months. Some gains persist beyond one year, though the rate of progress slows. Intensive rehabilitation optimises outcomes.
CIMT, involving restriction of the unaffected limb and intensive practice of the affected limb, shows evidence of motor improvement in selected patients with some residual hand function. Benefit is greatest when applied within 6 months of stroke.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung